Loading...

Cerenis Therapeutics Holding

BST:609
Snowflake Description

Adequate balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
609
BST
€7M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Cerenis Therapeutics Holding SA, a biopharmaceutical company, discovers and develops high density lipoprotein (HDL) therapies for the treatment of cardiovascular and metabolic diseases. The last earnings update was 220 days ago. More info.


Add to Portfolio Compare Print
  • Cerenis Therapeutics Holding has significant price volatility in the past 3 months.
609 Share Price and Events
7 Day Returns
3.6%
BST:609
-0.7%
DE Biotechs
2.5%
DE Market
1 Year Returns
-82.4%
BST:609
-9.2%
DE Biotechs
-6.7%
DE Market
609 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Cerenis Therapeutics Holding (609) 3.6% -9% -31.5% -82.4% - -
DE Biotechs -0.7% 4.7% -6.2% -9.2% 44% 8.7%
DE Market 2.5% 3.3% 9.2% -6.7% 9% 13.5%
1 Year Return vs Industry and Market
  • 609 underperformed the Biotechs industry which returned -9.2% over the past year.
  • 609 underperformed the Market in Germany which returned -6.7% over the past year.
Price Volatility
609
Industry
5yr Volatility vs Market

Value

 Is Cerenis Therapeutics Holding undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Cerenis Therapeutics Holding. This is due to cash flow or dividend data being unavailable. The share price is €0.3445.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Cerenis Therapeutics Holding's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Cerenis Therapeutics Holding's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BST:609 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-06-30) in EUR €-0.42
ENXTPA:CEREN Share Price ** ENXTPA (2019-04-18) in EUR €0.35
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.53x
Germany Market PE Ratio Median Figure of 421 Publicly-Listed Companies 19.69x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Cerenis Therapeutics Holding.

BST:609 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ENXTPA:CEREN Share Price ÷ EPS (both in EUR)

= 0.35 ÷ -0.42

-0.84x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Cerenis Therapeutics Holding is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Cerenis Therapeutics Holding is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Cerenis Therapeutics Holding's expected growth come at a high price?
Raw Data
BST:609 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.84x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
-8.2%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.31x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Cerenis Therapeutics Holding, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Cerenis Therapeutics Holding's assets?
Raw Data
BST:609 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-06-30) in EUR €0.30
ENXTPA:CEREN Share Price * ENXTPA (2019-04-18) in EUR €0.35
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.85x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.87x
BST:609 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ENXTPA:CEREN Share Price ÷ Book Value per Share (both in EUR)

= 0.35 ÷ 0.30

1.18x

* Primary Listing of Cerenis Therapeutics Holding.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Cerenis Therapeutics Holding is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Cerenis Therapeutics Holding's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Cerenis Therapeutics Holding has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Cerenis Therapeutics Holding expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-8.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Cerenis Therapeutics Holding expected to grow at an attractive rate?
  • Unable to compare Cerenis Therapeutics Holding's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Cerenis Therapeutics Holding's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Unable to compare Cerenis Therapeutics Holding's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
BST:609 Future Growth Rates Data Sources
Data Point Source Value (per year)
BST:609 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts -8.2%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.4%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BST:609 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (9 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BST:609 Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 -8
2020-12-31 0 -8 2
2019-12-31 0 -8 2
2018-12-31 0 -6 -5 2
BST:609 Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2018-06-30 -7 -8
2018-03-31 -8 -6
2017-12-31 -9 -5
2017-09-30 -11 -8
2017-06-30 -13 -11
2017-03-31 -16 -18
2016-12-31 -19 -25
2016-09-30 -19 -25
2016-06-30 -19 -24
2016-03-31 -16 -20
2015-12-31 -14 -17
2015-09-30 -11 -13

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Cerenis Therapeutics Holding is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Unable to determine if Cerenis Therapeutics Holding is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BST:609 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (9 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Cerenis Therapeutics Holding Company Filings, last reported 9 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:609 Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 -0.44 -0.44 -0.44 1.00
2020-12-31 -0.38 -0.35 -0.42 2.00
2019-12-31 -0.37 -0.34 -0.41 2.00
2018-12-31 -0.31 -0.27 -0.33 3.00
BST:609 Past Financials Data
Date (Data in EUR Millions) EPS *
2018-06-30 -0.42
2018-03-31 -0.35
2017-12-31 -0.27
2017-09-30 -0.44
2017-06-30 -0.60
2017-03-31 -0.99
2016-12-31 -1.39
2016-09-30 -1.37
2016-06-30 -1.36
2016-03-31 -1.19
2015-12-31 -1.00
2015-09-30 -0.86

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Cerenis Therapeutics Holding will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Cerenis Therapeutics Holding's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Cerenis Therapeutics Holding has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Cerenis Therapeutics Holding performed over the past 5 years?

  • Cerenis Therapeutics Holding's last earnings update was 220 days ago.
The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Cerenis Therapeutics Holding's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Cerenis Therapeutics Holding does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Cerenis Therapeutics Holding's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Cerenis Therapeutics Holding's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Cerenis Therapeutics Holding's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Cerenis Therapeutics Holding Company Filings, last reported 9 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:609 Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-06-30 -7.68 2.30 4.44
2018-03-31 -6.33 2.02 4.67
2017-12-31 -4.98 1.74 4.90
2017-09-30 -7.95 2.85 6.91
2017-06-30 -10.92 3.96 8.92
2017-03-31 -17.89 5.50 12.96
2016-12-31 -24.87 7.03 17.00
2016-09-30 -24.55 6.35 17.27
2016-06-30 -24.24 5.68 17.54
2016-03-31 -20.44 4.30 15.05
2015-12-31 -16.64 2.91 12.56
2015-09-30 -13.32 2.90 9.43
2015-06-30 -10.01 2.88 6.29
2015-03-31 -8.28 2.92 4.69
2014-12-31 -6.56 2.97 3.10
2013-12-31 -7.74 2.87 6.94

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Cerenis Therapeutics Holding has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Cerenis Therapeutics Holding has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Cerenis Therapeutics Holding improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Cerenis Therapeutics Holding's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Cerenis Therapeutics Holding has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Cerenis Therapeutics Holding's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Cerenis Therapeutics Holding's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Cerenis Therapeutics Holding is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Cerenis Therapeutics Holding's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Cerenis Therapeutics Holding's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 2.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Cerenis Therapeutics Holding Company Filings, last reported 9 months ago.

BST:609 Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-06-30 5.49 6.69 13.51
2018-03-31 5.49 6.69 13.51
2017-12-31 8.89 6.22 16.27
2017-09-30 8.89 6.22 16.27
2017-06-30 13.22 5.67 20.34
2017-03-31 13.22 5.67 20.34
2016-12-31 14.61 7.06 24.68
2016-09-30 14.61 7.06 24.68
2016-06-30 22.36 6.58 32.87
2016-03-31 22.36 6.58 32.87
2015-12-31 33.20 6.09 42.95
2015-09-30 33.20 6.09 42.95
2015-06-30 42.21 0.00 50.66
2015-03-31 42.21 0.00 50.66
2014-12-31 0.01 4.99 7.84
2013-12-31 6.16 0.00 11.14
  • Cerenis Therapeutics Holding's level of debt (122%) compared to net worth is high (greater than 40%).
  • Unable to establish if Cerenis Therapeutics Holding's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Cerenis Therapeutics Holding has sufficient cash runway for 2 years based on current free cash flow.
  • Cerenis Therapeutics Holding has sufficient cash runway for 2.1 years if free cash flow continues to reduce at historical rates of -11.8% each year.
X
Financial health checks
We assess Cerenis Therapeutics Holding's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Cerenis Therapeutics Holding has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Cerenis Therapeutics Holding's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Cerenis Therapeutics Holding dividends. Estimated to be 0% next year.
If you bought €2,000 of Cerenis Therapeutics Holding shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Cerenis Therapeutics Holding's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Cerenis Therapeutics Holding's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BST:609 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 324 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BST:609 Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2021-12-31 0.00 1.00
2020-12-31 0.00 2.00
2019-12-31 0.00 2.00
2018-12-31 0.00 3.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Cerenis Therapeutics Holding has not reported any payouts.
  • Unable to verify if Cerenis Therapeutics Holding's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Cerenis Therapeutics Holding's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Cerenis Therapeutics Holding has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Cerenis Therapeutics Holding's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Cerenis Therapeutics Holding's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Cerenis Therapeutics Holding afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Cerenis Therapeutics Holding has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Cerenis Therapeutics Holding's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Richard Pasternak
COMPENSATION €43,000
TENURE AS CEO 0.3 years
CEO Bio

Dr. Richard C. Pasternak, MD serves as an Advisor of Bay City Capital LLC. He is also an Advisor at Bay Capital LLC. Dr. Pasternak serves as Medical Director of the Cardiology Practice Plan at Massachusetts General Hospital. He is a faculty member of the Weill Cornell School of Medicine. Dr. Pasternak also served as the Director of Preventive Cardiology & Cardiac Rehabilitation at Massachusetts General Hospital from 1992 to 2004 and an Associate Professor of Medicine at the Harvard Medical School, having been on the Harvard faculty since 1983. Previously, he served as Vice President, Head of Cardiovascular Clinical Research and Head Cardiovascular Therapeutic Area from 2004 to 2008 and Head of Global Scientific Affairs and Scientific Leadership at Merck & Co from 2008 to 2010. Dr. Pasternak also served as a key Senior Executive in a communications role for Merck regarding critical issues related to scientific affairs and was a policy liaison for medical and scientific issues. He serves as Chairman of The Scientific Advisory Board of Essentialis, Inc. and served as its Lead Scientific Advisor since December 12, 2011. He has been Chairman of the Board at Cerenis Therapeutics Holding SA since May 28, 2014. He has been Non-Executive Director at Cerenis Therapeutics Holding SA since October 26, 2011 and serves as its Chief Executive Officer since December 18, 2018. He has been a Director of Essentialis, Inc. since December 12, 2011. He serves as a Member of the Medical Advisory Board of Nurtur Health, Inc. (aka Cardium Health Services Corp.). He serves on the Boards of the Founder's Affiliate of the American Heart Association, the Galien Foundation and Essentialis Therapeutics. He served as Director of Coronary Care Unit at Beth Israel Hospital. He has extensive research experience in lipid disorders and the impact of lipid therapies on coronary disease and its complications. He completed his medical internship, residency training and cardiology fellowship at Massachusetts General Hospital. He received his B.A. and M.D. from Yale University.

CEO Compensation
  • Richard's compensation has been consistent with company performance over the past year.
  • Richard's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Cerenis Therapeutics Holding management team in years:

2.3
Average Tenure
59
Average Age
  • The tenure for the Cerenis Therapeutics Holding management team is about average.
Management Team

Richard Pasternak

TITLE
Chairman & CEO
COMPENSATION
€43K
TENURE
0.3 yrs

Jean-Louis Dasseux

TITLE
Co- Founder & Director
COMPENSATION
€464K
AGE
59
TENURE
14.3 yrs

Christian Chavy

TITLE
Chief Executive Officer of Stallergenes & Director
COMPENSATION
€3K
AGE
68
TENURE
0.3 yrs

Cyrille Tupin

TITLE
Chief Financial & Administrative Officer and Deputy CEO

Emmanuel Fougeroux

TITLE
Chief Accounting Officer

Renée Benghozi

TITLE
Chief Medical Officer
TENURE
4.2 yrs

Gavin Sy

TITLE
Chief Production Officer

Constance Keyserling

TITLE
Senior Vice President of Clinical Development
AGE
57
Board of Directors Tenure

Average tenure and age of the Cerenis Therapeutics Holding board of directors in years:

3.9
Average Tenure
59
Average Age
  • The tenure for the Cerenis Therapeutics Holding board of directors is about average.
Board of Directors

Richard Pasternak

TITLE
Chairman & CEO
COMPENSATION
€43K
TENURE
4.9 yrs

Jean-Louis Dasseux

TITLE
Co- Founder & Director
COMPENSATION
€464K
AGE
59

Christian Chavy

TITLE
Chief Executive Officer of Stallergenes & Director
COMPENSATION
€3K
AGE
68
TENURE
4.2 yrs

Karen Noël

TITLE
Director
TENURE
1.8 yrs

Briggs Morrison

TITLE
Chairman of Scientific Advisory Board
AGE
58
TENURE
0.9 yrs

John Kastelein

TITLE
Member of Scientific Advisory Board
AGE
64
TENURE
12.1 yrs

Michael Davidson

TITLE
Independent Director
COMPENSATION
€4K
AGE
61
TENURE
4.3 yrs

Olivier Martinez

TITLE
Board Observer
AGE
48
TENURE
3.8 yrs

Laura Coruzzi

TITLE
Independent Director
COMPENSATION
€3K
TENURE
3.9 yrs

Mark Frohlich

TITLE
Member of Scientific Advisory Board
AGE
56
TENURE
0.9 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Cerenis Therapeutics Holding's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Cerenis Therapeutics Holding has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Cerenis Therapeutics Holding SA, a biopharmaceutical company, discovers and develops high density lipoprotein (HDL) therapies for the treatment of cardiovascular and metabolic diseases. It is developing a portfolio of HDL therapies, which include HDL mimetics for the rapid regression of atherosclerotic plaque in high-risk patients. The company is developing CER-001, an engineered complex of recombinant human apoA-I, the structural protein of HDL, and phospholipids that is in Phase II clinical trials designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; and CER-209, a drug candidate that is in Phase I clinical trial for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis. Cerenis Therapeutics Holding SA was founded in 2005 and is based in Labege, France.

Details
Name: Cerenis Therapeutics Holding SA
609
Exchange: BST
Founded: 2005
€6,665,099
18,827,965
Website: http://www.cerenis.com
Address: Cerenis Therapeutics Holding SA
33-43 av. Georges Pompidou – Bât. D2,
Labege,
Midi-Pyrénées, 31130,
France
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ENXTPA CEREN Common Shares Euronext Paris FR EUR 30. Mar 2015
OTCPK THRP.F Common Shares Pink Sheets LLC US USD 30. Mar 2015
DB 609 Common Shares Deutsche Boerse AG DE EUR 30. Mar 2015
BST 609 Common Shares Boerse-Stuttgart DE EUR 30. Mar 2015
LSE 0RAG Common Shares London Stock Exchange GB EUR 30. Mar 2015
BATS-CHIXE CERENp Common Shares BATS 'Chi-X Europe' GB EUR 30. Mar 2015
Number of employees
Current staff
Staff numbers
7
Cerenis Therapeutics Holding employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/18 22:18
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/17
Last earnings filing: 2018/09/10
Last earnings reported: 2018/06/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.